Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: Kingfisher who wrote (435)	6/15/1998 12:59:00 PM
From: OLD JAKE JUSTUS	Read Replies (1) \| Respond to of 4891

A great post, Sir!

To: Kingfisher who wrote (435)	6/15/1998 1:22:00 PM
From: jmt	Read Replies (1) \| Respond to of 4891

Mr. Kingfisher... I am unfortunately well versed in Quantitative analysis, multiple regression techniques and all related sadistical (pun intended) modeling methods. My post was in fact to support what you have so articulated stated, there is no historical info with this company that could be used to model projected price. Bu truely if Mr. Hirschman's preditions are grounded in reality concerning the projected revenue, and sustainability of that revenue give the business risks, ie competitive products or discoveries, the share price could predictively trade outside 3 standard deviations (99.5% confidence) from the mean biotech P/E. My head hurts. Can you say Heteroskedasticity? jmt

To: Kingfisher who wrote (435)	6/15/1998 3:09:00 PM
From: paper man	Respond to of 4891

Kingfisher... do you think todays USA Today article and the AP release are a sign of changes coming.? In my model, this one gets applied to SCIENCE. I feel that todays article is solid news for AVR as it is! Science talks. 6 weeks ago we had Gallo talking about determining the real value of protease inhibitors . This does not seem like a good start. The real value of medicine is to gain the farthest success with the least digression from treatment. After 1 1/2 years, time for a different approach. I speculate that when we see US trials, one study group will be of those described in the article. Drop the PIs and bring in the R. good luck